Menu Search Donate
Drug dosage identifier


This document is only valid for the day on which it is accessed. Please read our disclaimer.

Dose and administration

0.2mg/kg/day PO daily.

Any variation in dosing, to be discussed with Cardiologist/Neonatal Specialist


  1. Adjunct to thiazides or furosemide to conserve potassium. 
  2. Not used as primary diuretic. 

Contraindications and precautions

  1. Infants with hyperkalaemia.
  2. Caution in renal or hepatic impairment. 
  3. Caution in renal impairment in infants receiving digoxin therapy. Possible increase in serum digoxin levels. 
  4. Caution with concomitant administration of IVN. May cause possible metabolic acidosis. 
  5. Avoid supplemental potassium. 

Clinical pharmacology

Amiloride hydrochloride is a weak diuretic with potassium sparing properties. It also exhibits natriuretic and hypotensive effects. It is chemically unrelated to other known diuretics. Amiloride acts directly on the distal renal tubule of the nephron to inhibit sodium-potassium ion exchange. Unlike spironolactone, amiloride does not competitively inhibit aldosterone and its diuretic activity is independent of aldosterone.

It is completely absorbed from the gastrointestinal tract. Simultaneous administration of food decreases gastrointestinal absorption from about 50% to about 30%. The drug has large extravascular distribution. It is not significantly bound to human plasma protein. Amiloride is not metabolised and is eliminated by the kidney (50%) and in the faeces (about 40%).

Onset of action about 2 hours and its diuretic action reaches a peak in 6 - 10 hours and may persist for about 24 hours.

Possible adverse effects

  1. Hyperkalaemia (signs and symptoms: lethargy, paralysis of the extremities, bradycardia, shock and ECG abnormalities). 
  2. Hyponatraemia. 
  3. Gastrointestinal disturbances (nausea, vomiting, diarrhoea or constipation). 
  4. Metabolic acidosis. 
  5. Transient elevation in BUN and serum creatinine. 
  6. Rash.

Special considerations

  1. Monitor urea and electrolytes frequently when commenced. Anticipate hyperkalaemia, hyponatraemia.
  2. It should be given with care to patients likely to develop metabolic acidosis. 
  3. Amiloride has been shown to increase serum digoxin levels. 
  4. Safety and efficacy of amiloride in children alone or in combination with hydrochlorothiazide has not been established. 
  5. Avoid supplemental potassium. 
  6. Decreased diuretic effectiveness with NSAIDS avoid concomitant use. 

Management of amiloride administration


Is a 1mg/ml solution dispensed by Pharmacy. Preservative free.


Charted on prescription chart in mg/dose.


Administer independent of food (milk decreases bioavailability).

Nursing considerations

  1. Assess for signs of adverse effects. Be alert for signs of hyperkalaemia, hyponatraemia.
  2. Monitor fluid balance.
  3. Monitor blood pressure at regular intervals.
  4. Weigh each 2-3 days.


  • Refrigerate. Do NOT freeze.
  • Expires 7 days from opening.


  1. Paediatric Pharmacopoeia, Royal Children's Hospital, Melbourne 2002 
  2. British National Formulary 2012-13. BMJ Group, the Royal Pharmaceutical Society of Great Britain, and RCPCH Publications Ltd 20121
  3. McEvoy GK (ed) AHFS. Drug information. Bethesda American Society of Hospital Pharmacists Inc, 2010. 
  4. Reynolds JEF (ed) Martindale. The Extra Pharmacopoeia (30th ed) London: The Pharmaceutical Press 1993. 
  5. Nursing 1997. Drug handbook, Springhouse, p810-1.

Did you find this information helpful?

Document Control

  • Date last published: 31 July 2012
  • Document type: Drug Dosage Guideline
  • Services responsible: Neonatology
  • Editor: Sarah Bellhouse
  • Review frequency: 2 years